Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15p -3.95% 3.65p 862,609 16:23:19
Bid Price Offer Price High Price Low Price Open Price
3.50p 3.80p 3.80p 3.60p 3.80p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.43 -0.26 -0.31 2.6

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Takeover Rumours

Physiomics (PYC) Share Charts

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart

Intraday Physiomics Chart

Intraday Physiomics Chart

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
15/1/201909:07Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni4,248
20/11/201814:33Physiomics with Charts & News13,709
31/1/201808:34PHYSIOMICS plc Virtual Tumor platform4,933
01/12/201719:18RGP NEXT MULTI BAGGER TODAY 50p4
01/12/201707:35Timbeeerrr back to reality -

Add a New Thread

Physiomics (PYC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
19/1/2019
08:20
Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 3.80p.
Physiomics Plc has a 4 week average price of 3.50p and a 12 week average price of 3.50p.
The 1 year high share price is 13.20p while the 1 year low share price is currently 3.40p.
There are currently 71,910,394 shares in issue and the average daily traded volume is 367,823 shares. The market capitalisation of Physiomics Plc is £2,624,729.38.
13/12/2018
10:50
badger60: Institutional OwnershipInstitutions account for 77.04% of PYC's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. Although PYC has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. In the case of PYC, investors need not worry about such volatility considering active hedge funds don't have a significant stake. However, we should dig deeper into PYC's ownership structure and find out how other key ownership classes can affect its investment profile.Insider OwnershipInsiders form a group of important ownership types as they manage the company's operations and decide the best use of capital. Insider ownership has been linked to better alignment between management and shareholders. Although individuals in PYC hold only a 1.98% stake, it's a good sign for shareholders as the company's executives and directors have their incentives directly linked to the company's performance. In addition to this, it may be interesting to look at insider buying and selling activities. Keep in mind that buying may be sign of upbeat future expectations, but selling doesn't necessarily mean the opposite as the insiders might just be doing it out of their personal financial needs.General Public OwnershipThe general public holds a substantial 20.92% stake in PYC, making it a highly popular stock among retail investors. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. This is a positive sign for an investor who wants to be involved in key decision-making of the company.Private Company OwnershipAnother group of owners that a potential investor in PYC should consider are private companies, with a stake of 0.028%. While they invest more often due to strategic interests, an investment can also be driven by capital gains through share price appreciation. However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence PYC's business strategy. Thus, investors not need worry too much about the consequences of these holdings.
21/11/2018
19:21
the stigologist: The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector. Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past." The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC). Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m However when considering how to value Physiomics it's important to realise there are two major strands to it's business. One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m) The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS. e.g. Oesophagal Cancer study hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/completion-of-innovate-uk-grant-project/201803120700073209H/ Prostate Cancer study hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/award-of-new-innovate-uk-grant/201803140700036050H/ This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m. Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m. In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.
20/11/2018
12:09
badger60: Yep .... relatively modest value contracts going forward will add multiples to the share price. On a p/e of 10.....3mio revenues gives a X10 multiple of today's share price
06/9/2018
23:30
davevt: No you're missing my point. Think of the mid point as a flag on a rope constantly being pulled back and forth. The price you see on a site isn't live, it's lagged and delayed. The mid point price is constantly moving. So when you see a buy or sell reported, it's delayed, and it can simply be at the time of reporting the mid point as moved, the buy price is now below the mid point and 'reported as a sell'. It makes no difference what so ever. If the share price was 4 for instance, and then the bid was put up to 4.5 and an ask of 5, and all the trades that day were sells, the share price would go up would it not? Once again, it matters not if it's a buy or a sell, it's a TRADE, at a price.
10/6/2018
14:31
pwhite73: OBD The current share price does not represent or misrepresent any value. The current share price is where mug punters are buying in order to support the next placing. The value of an AIM company and its share price completely divorced about 5 years ago. When was the last time you heard the term Price Earnings Ratio applied to an AIM stock. It cannot be that PYC was worth 32p per share in December 2017 valuing the company at £19 million and today the placing has valued the same company at just £2.8 million. Where has £16 million of value disappeared to in the space of seven months. You may not know where the share price will be in one years time but I certainly do. It will be back to 1p and this time it will stay there because mug punters are not going to be fooled again (he thinks!!). I have stated before and I'll say so again if it had not been for the November 2017 frenzy I believe PYC would have sought to exit from the AIM.
10/6/2018
12:40
guss: For a more balanced view of the recent rise and fall of the share price I always read PWhites comments as they appear to me as well researched, polite and intelligent comments, always welcomed, but in this case not completely accurate. My experience of PYC over the past ten years, I think, it sure seems like that: I have profited in 3 out of the last 4 emotional price rises and missed the the boat at least once. Just before Christmas I looked at my 100,000 PYC shares, they had cost me over £7000 due to averaging down over the years but they were only worth £900. I considered cutting my loses and taking the £900 to spend on Christmas, or adding another £900 to the pot and doubling my holding. Luckily, and sadly, I did nothing. A week or so later the share price had gone from 0.9p to 32p. Having been in the red for 99% of the time that I held these shares I sold some of them at 12p ish more at 23p on the way up and then at 18p on the way down and then finally, after a few days of pondering if I should buy more, I sold the last of my holding at about 7p. Maybe I’m one of the lucky ones but I had no problem selling, they were gobbled up and I received £24k approx from the sale, although this did include my original stake which to be honest I had written off. I’m still watching these but I don’t want to be locked in for another 10 years, not with £7k worth anyway. If they do drop down to below 2p I might chuck a couple of grand at them. I think PWhite is probably right about the AIM way of funding a company, as close to a scam as you can get. But you can sell on a rise, for whatever reason, at least I did 😁
22/4/2018
13:04
the stigologist: PYC Physiomics (Share Price 6p ; Shares o/s 58m ; Mkt Cap £3.5m) On November 30th 2017 the ex-Founder of Physiomics made the following points in a long post in which he also claimed he believed PYC should be worth over 100p+ *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. htTp://uk.advfn.com/cmn/fbb/thread.php3?id=31109702&from=3710 Since then the Physiomics management have on a number of occasions talked about Personalised Medicine, Cloud technology, AI (Artificial Intelligence) e.g. Interim Results February 2018 hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/interim-results-statement/201802190700021669F/ "We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process." ... "This grant project, focused on the personalisation of oesophageal cancer treatment, has driven insights that may be integrated into our core Virtual Tumour offering and will also be the subject of thought capital that will be exploited over the course of this calendar year at industry conferences and through the publication of scientific papers in order to garner further interest from the drug research community. Finally, the ideas generated by this project have the potential to be taken forward in a further personalised medicine project for which the Company is currently seeking funding." Having presented 'successfully' last week at the AACR conference in Chicago,US, this coming week they will present on Tuesday 24th April 2018 at BioTrinity in the UK (Europe's leading Investment and Partnering conference for the BioPharma industry). Following that their previous funding partners the Government Innovate UK body will be launching a Personalised Medicine investment accelerator looking to invest £0.5m-1.5m in projects run by SMEs. hTtps://www.eventbrite.co.uk/e/leveraging-publicprivate-investment-tickets-44180316516 Now clearly a £3m company like Physiomics winning a big funding contract like that would be both an immense validation of their technology and approach but also fund their in a NON-DILUTIVE manner for many years. It's interesting that the UK Government is funding SMEs to tackle the Holy Grail of Personalised Medicine but there are other massive AI companies involved who could I suggest partner with Physiomics. Imagine £3m Physiomics announcing a deal with Jeff Bezos' $1bn+ cancer detection/personalised medicine start-up/roll-up Grail or how about with Google's UK AI specialist DeepMind (which they bought for $500m) and has an operation called DeepMind Health looking to work with Academics and the NHS for cancer detection/personalised medicine. This is something the market has not considered as of yet because they still see PYC as simply being a Company that will have biotechs and Pharmas as potential customers. htTps://theconversation.com/deepmind-can-we-ever-trust-a-machine-to-diagnose-cancer-88707 htTps://healthitanalytics.com/news/cancer-detection-company-gets-900m-from-pharma-vc-investors "GRAIL, Inc., a precision medicine and life sciences company aiming to develop new very early detection techniques for cancer, has attracted more than $900 million in investment capital from some of the most well-known names in pharmaceutical sales and development. Bristol-Myers Squibb, Celgene, Merck, and Johnson & Johnson Innovations have joined with other strategic investors, including Amazon’s Jeff Bezos and McKesson Ventures, to contribute hundreds of millions to the company’s financial future. “We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, GRAIL’s Chief Executive Officer. “I believe that GRAIL’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science is unparalleled in the field of cancer detection."
27/12/2017
11:08
margic: It's a good thing for the PYC share price that eyes have just come off this. As buyers start to return this can move very very quick before the herd arrive and when the herd arrive we spike. Signal to take profit and re-load as the herd exit with their losses and smaller profits. Hope to see this 10p+ before volumes really pick up. Keep watch as PYC can flash bang wallop!
18/12/2017
09:06
the stigologist: Todays VAL Valirx news on VAL201 is also great news for PYC. Expect PYC share price to follow VAL up
17/12/2017
11:28
margic: Great stuff mate and exactly what I was hoping for, you've opened the doors for everyone to take note and find where to search, it's research and posts like that, that can move a stock and why not, there new information to see for investors to start predicting a value and assessing the share price tools to decide if PYC represents value. Centara is a great example, I highly doubt PYC would be taken out for anywhere near that figure based on the past but then again, was it here I read the directors have been ousted? That might change the picture. The bod I remember for years ago were no good to share holders but then again, why would you want long term shareholders when you have a big big play behind closed doors and a shocking share price. Price makes the mouth water now. 11.5p circa £6mil market cap, in a market that can quickly add £50mil valve on anything material that investors can put there eyes on. Even the $32mil take over in 2012 coming out of the burst. More money is spent now and it doesn't take much for a big boy to offer £35-50mil for a small slice, it helps them balance their spending. As I understand it, big pharmacy have a budget quota that must be spent year on year on certain aspects of the business and accumulating businesses, investment partnerships, support and R&D have the highest budgets set in both fiscal cash and time. These budgets. I may be wrong but GSK used to spend like 1bil dollars min a year on failed products before the 80's even. Certainly with now only 57odd mil shares in circulation this is a good time for PYC. I'm sure they can prove the markets cap to £12-15mil and then raising money to boost the line will become comfortable. Unless a take over offer happens out of no where you'd have to expect PYC to place just over 100mil shares, but it's very possible they could secure £10-30mil doing that. Big money for them, not sure they've ever had that at their disposal. As always it will be down to the bod and how soon they want to make their money. Many old money directors have 50-75years for their plays to come good.Is there any key news expected from the faithful? How do you see the BOD moving the company going forward, has anyone meet them or heard them speak? Thanks for the informative stuff stig. I'm only just flirting back in the aim market, I'm a technical trader now with currency's but I do like the aim. It seems now is like 2007-2011 all over again. Rises do seem much bigger. A good start for me has been some of the oldies im familiar with have been squeezed almost to the max and everything is jumping like true penny stocks should.PYC for starters, great news, big share price jump, hype, 57 something mil shares £6mil value, same as always, jumped in with 3mil market cap, can always go £12-15mil outta now where £35-50mil on transformational news, and £100mil + on a well sourced city take over rumour or bid. Bid less likely in normal terms but then again, Takeovers in the Pharma game are normally as good if not better than the tech industry. Disney splashing out £34bil, for essentially parts of a business, imagine what big pharmacy made will pay to wrap a deal up quick. It's not a ramp but I do know if GSK want a business they think a rival will want, they make an offer that won't be matched to conduct a move super quick. If PYC was valued by a proper surveying team at say £65mil (figure I've come up with based off others) , and no one was interested then it's a 20mil offer for part. If other firms are interested it's £80mil+, if a major rival is sniffing, £150-180mil+ plus part retention, if they feel a rival will bid, they'll re-visit alternatives, if they believe PYC to be better than all the rest, then you could be actually looking £500mil + you get a bidding war on that, who knows from there. That's how I see it.
Physiomics share price data is direct from the London Stock Exchange
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190120 06:45:10